| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Rivastigmine carbamate impurity does not have a specific pharmacological target as it is an impurity. The parent compound rivastigmine targets both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), acting as a potent and orally active cholinesterase inhibitor. It works by increasing the amount of acetylcholine in the brain.
|
|---|---|
| ln Vitro |
Rivastigmine carbamate impurity is not pharmacologically active; it serves as a reference standard for impurity profiling. It exhibits different physicochemical properties compared to rivastigmine. The compound is used in quality control to identify and quantify impurities in rivastigmine drug substance and products. Cellular assays for Rivastigmine carbamate impurity are not applicable, as it is not a pharmacologically active compound. However, it may be used in cell-based assays to study the effects of impurities on cell viability or function.
|
| ln Vivo |
In vivo, Rivastigmine carbamate impurity is not intended for therapeutic use. It is a byproduct found in rivastigmine. Its presence is monitored to ensure the quality and safety of rivastigmine drug products.
|
| Enzyme Assay |
Cell-free assays for Rivastigmine carbamate impurity are not typically performed for pharmacological activity. Instead, it is used as a reference standard in analytical methods, such as HPLC, to identify and quantify the impurity in rivastigmine samples.
|
| Cell Assay |
Cellular assays using Rivastigmine carbamate impurity are limited to its use as a reference standard. It may be used in cell culture to study the potential toxic effects of impurities. However, such studies are not standard.
|
| Animal Protocol |
In vivo studies on Rivastigmine carbamate impurity are not conducted, as it is not a therapeutic agent. Its safety profile is assessed as part of the overall impurity profile of rivastigmine.
|
| Toxicity/Toxicokinetics |
Rivastigmine carbamate impurity is not a therapeutic agent and toxicity studies are not applicable to it as a standalone compound. Its presence is controlled in rivastigmine drug products to ensure patient safety.
|
| References |
|
| Additional Infomation |
Rivastigmine carbamate impurity is a reference standard used in pharmaceutical quality control for rivastigmine. It is a byproduct found in rivastigmine and is used to identify and quantify impurities in the drug substance and drug product. It is not intended for therapeutic use.
|
| Molecular Formula |
C10H12N2O4
|
|---|---|
| Molecular Weight |
224.21
|
| Exact Mass |
224.08
|
| CAS # |
1346242-31-6
|
| PubChem CID |
72942021
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.568
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
264
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN(C)C(=O)OC1=CC=CC(=C1)[N+](=O)[O-]
|
| InChi Key |
DFECCKHSYUWCIJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H12N2O4/c1-3-11(2)10(13)16-9-6-4-5-8(7-9)12(14)15/h4-7H,3H2,1-2H3
|
| Chemical Name |
(3-nitrophenyl) N-ethyl-N-methylcarbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (446.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4601 mL | 22.3005 mL | 44.6010 mL | |
| 5 mM | 0.8920 mL | 4.4601 mL | 8.9202 mL | |
| 10 mM | 0.4460 mL | 2.2301 mL | 4.4601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
